Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
NEW YORK, NY, May 02, 2018 -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8th at 12:50pm EDT. Tom LaVoy, CEO of IsoRay, will be presenting as well as meeting with investors.
Tom LaVoy, IsoRay’s CEO, will also be a participant on a panel discussion at 1:45pm EDT entitled “Disruptive Injectables & Oncology”.
The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
For those interested in attending, please visit www.DisruptNYC.com for more information.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter@IsoRay.
About RHK Capital:
Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.
Contacts: IsoRay Inc. [email protected] (509) 375-1202 Investors: Stephanie Prince, Managing Director PCG Advisory Group [email protected] (646) 762-4518
